We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly’s COVID-19 Antibody Therapy Slashes Risk of Hospitalization and Death
Eli Lilly’s COVID-19 Antibody Therapy Slashes Risk of Hospitalization and Death
Eli Lilly said its combination antibody therapy, bamlanivimab and etesevimab, reduced the risk of hospitalization and death by 87 percent in a late-stage study of 769 high-risk COVID-19 patients — and worked against emerging variant strains of the coronavirus.